Senate Finance Committee Holds Hearing on FDA’s Foreign Drug Manufacturing Inspection Process
On June 2, 2020, the Senate Committee on Finance hosted a full Committee hearing entitled “COVID-19 and Beyond: Oversight of the FDA’s Foreign Drug Manufacturing Inspection Process.” Witnesses represented the U.S. Food and Drug Administration (FDA), U.S. Government Accountability Office (GAO), and private sector companies. The hearing sought to examine the accountability of FDA’s vetting process, especially in regard to drugs necessitated by the COVID-19 pandemic. Lawmakers and witnesses in the public and private sector discussed FDA’s current policy and future measures to increase onshoring and prevent the influx of drugs from unsafe supply chains. For more information, please read the full memorandum.
BERGESON & CAMPBELL, P.C.
2200 Pennsylvania Ave., N.W.
Washington, D.C. 20037
(202) 557-3836 (fax)